J2KBIO Co (420570) Fair Value & Analysis
Basic Materials · KR · Market cap 45.7B KRW
Fair value as of: Jul 21, 2026
From 24 valuation models · updated 21 days ago
Share price +29.6% over the past month.
A solid business, but screening 13% overvalued on our models.
What matters now
- Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
- Our model range runs from 6,856 KRW (bear) to 11,427 KRW (bull), base 9,142 KRW. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 53/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (2 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
29‑month range 6,950 KRW – 32,488 KRW · fair‑value band 6,856 KRW – 11,427 KRW · the 10,560 KRW price screens above the 9,142 KRW fair value. Dashed = 300-day average. As of Jul 21, 2026.
Analysis
J2KBIO Co (420570) currently trades at 10,560 KRW, while our model-based Fair Value estimate is 9,142 KRW, implying the stock looks roughly 13.4% overvalued today. The Quality Score stands at 53/100 (solid quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, J2KBIO Co generated revenue of 36.8B KRW at a net margin of 10.9%. Revenue grew 53.1% year over year. It earns a return on equity of 12.4%. Fundamentals as of Jul 21, 2026
Our scenario range runs from 6,856 KRW (bear case) to 11,427 KRW (bull case); at 10,560 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 11% below its 52-week high and 51% above its 52-week low, currently above its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -58% fair-value upside, at -13%, 420570 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (11,908 KRW) versus Asset-Based (3,870 KRW). Highest evidence: Growth DCF (80).
Notify me when 420570 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 58
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
J2KBIO Co., Ltd., a bio venture company, offers active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation. The company was founded in 2014 and is based in Cheongju, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
J2KBIO Co reported revenue of 33.0B KRW in FY2025 versus 14.2B KRW in FY2021, a compound +23.4%/yr. Reported net income was 2.7B KRW in FY2025, compounding +13.3%/yr from FY2021.
420570 screens 13% overvalued. Compare with Linde plc →
Peer Group
Specialty Chemicals · 673 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Specialty Chemicals median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Linde plc LIN | $489.98 | $222.03 | -55% |
| Nan Ya Plastics Corporation 1303 | 181.50 TWD | 255.83 TWD | +41% |
| Wanhua Chemical Group 600309 | ¥70.04 | ¥68.03 | -3% |
| Novozymes A/S NSISB | kr 428.20 | kr 179.66 | -58% |
| Asian Paints Limited ASIANPAINT | ₹2,689 | ₹668.81 | -75% |
| Solar Industries India Limited SOLARINDS | ₹18,236 | ₹2,793 | -85% |
| Pidilite Industries Limited PIDILITIND | ₹1,560 | ₹351.84 | -77% |
| PT Chandra Asri Pacific Tbk TPIA | 1,805 IDR | 2,888 IDR | +60% |
| Linde India Limited LINDEINDIA | ₹7,115 | ₹757.93 | -89% |
| Berger Paints India Limited BERGEPAINT | ₹493.70 | ₹164.29 | -67% |
Compare J2KBIO Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is J2KBIO Co (420570) overvalued or undervalued?
What is the fair value of 420570?
What is the quality score of 420570?
What is the revenue of J2KBIO Co (420570)?
What is the net profit margin of 420570?
Does J2KBIO Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track J2KBIO Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.